Antidiabetic drugs for T2DM can directly target hyperglycemia by promoting insulin release from beta cells in the early stages of the disease by improving insulin sensitivity of target cells through various pathways, or by slowing down carbohydrate digestion after a meal. This evidence concerns the gene INS and Hyperglycemia.